Fingerprinting a multiomics biomarker profile in patients with STXBP1-RD

Awardee: Pasquale Striano

Institution: University of Genoa

Grant Amount: $87,125.00

Funding Period: February 1, 2023 - January 31, 2024


Summary:

Mutations in STXBP1 gene lead to a complex and severe neurodevelopmental disorder (STXBP1-related disorders, -RD), with symptoms including intellectual disability, epilepsy, movement and behavioral disorders, and gastrointestinal (GI) symptoms. There is no cure to date, but targeted therapies for STXBP1 are under investigation. However, the variability of symptoms and severity of STXBP1-RD makes it challenging to evaluate the effect of a treatment during a clinical trial, so that we need to identify biomarkers of the disease that can be measured. We will explore these biomarkers in the metabolome and gut microbiome of patients with STXBP1-RD. Gut microbiome is the pool of microorganisms that live in our gut and constantly interacts with our organism, including with our brain (gut-brain axis). Bacteria produce a lot of substances that join our metabolome, which is the whole pool of substances present in our blood and produced or introduced in our organism. Alterations in microbiome and metabolome can be identified in many health conditions, including autism and epilepsy. We aim to identify specific alterations in the microbiome and metabolome profiles of patients with STXBP1-RD, that can be further investigated as biomarkers and as therapeutic targets.

Previous
Previous

Development of proof-of-concept Pitt-Hopkins Syndrome therapy by upregulation of TCF4 transcriptional activity

Next
Next

Assessing and quantifying gait problems in patients with STXBP1-related disorders using three-dimensional gait analysis